Evidence map›Paper›PMID 36240297›Full record

ArticleBlood advances2023

Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation.

James S Tweddell, Mousa Kharnaf, Farhan Zafar, Kyle W Riggs, James A Reagor, Brett P Monia, Alexey Revenko, Daniel G Leino, A Phillip Owens, Janine K Martin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Progress towards permanent respiratory support.Current opinion in organ transplantation · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

James S TweddellThe Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Mousa KharnafThe Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0001-6945-3671
Farhan ZafarThe Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Kyle W RiggsThe Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0001-8045-0738
James A ReagorThe Heart Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-4494-8026
Brett P MoniaIonis Pharmaceuticals, Inc, Carlsbad, CA.
Alexey RevenkoIonis Pharmaceuticals, Inc, Carlsbad, CA.ORCID 0000-0002-4863-362X
Daniel G LeinoDivision of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0001-9183-5617
A Phillip OwensDepartment of Internal Medicine, The University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0002-0835-620X
Janine K MartinCancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Benjamin GourleyCancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Leah RosenfeldtCancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Joseph S PalumboCancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH.
Cincinnati Children's Hospital Medical Center · USIonis Pharmaceuticals (United States) · USUniversity of Cincinnati Medical Center · US

Funding

The role of contact pathway factors in mechanical circulationR01HL160582 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI MORALES, DAVID L, PALUMBO, JOSEPH S. · 2022 to 2025
$2.2M
6 · The paper itself

Abstract

Previous studies suggested that contact pathway factors drive thrombosis in mechanical circulation. We used a rabbit model of veno-arterial extracorporeal circulation (VA-ECMO) to evaluate the role of factors XI and XII in ECMO-associated thrombosis and organ damage. Factors XI and XII (FXI, FXII) were depleted using established antisense oligonucleotides before placement on a blood-primed VA-ECMO circuit. Decreasing FXII or FXI to < 5% of baseline activity significantly prolonged ECMO circuit lifespan, limited the development of coagulopathy, and prevented fibrinogen consumption. Histological analysis suggested that FXII depletion mitigated interstitial pulmonary edema and hemorrhage whereas heparin and FXI depletion did not. Neither FXI nor FXII depletion was associated with significant hemorrhage in other organs. In vitro analysis showed that membrane oxygenator fibers (MOFs) alone are capable of driving significant thrombin generation in a FXII- and FXI-dependent manner. MOFs also augment thrombin generation triggered by low (1 pM) or high (5 pM) tissue factor concentrations. However, only FXI elimination completely prevented the increase in thrombin generation driven by MOFs, suggesting MOFs augment thrombin-mediated FXI activation. Together, these results suggest that therapies targeting FXII or FXI limit thromboembolic complications associated with ECMO. Further studies are needed to determine the contexts wherein targeting FXI and FXII, either alone or in combination, would be most beneficial in ECMO. Moreover, studies are also needed to determine the potential mechanisms coupling FXII to end-organ damage in ECMO.

Indexed as

Extracorporeal Membrane OxygenationThrombosisAnimalsFactor XIFactor XIIRabbitsThrombinFactor XIFactor XIIThrombin

Identifiers

PMID36240297
PMCPMC10139951
OpenAlexW4306194460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.